Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 21.69
(-2.58%)
USD 21.69
(-2.58%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 240.73 Million USD | -1.03% |
| 2022 | 243.23 Million USD | 75.89% |
| 2021 | 138.28 Million USD | 57.16% |
| 2020 | 87.99 Million USD | -47.87% |
| 2019 | 168.79 Million USD | 945.67% |
| 2018 | 16.14 Million USD | -48.6% |
| 2017 | 31.4 Million USD | 19736.49% |
| 2016 | 158.33 Thousand USD | -58.55% |
| 2015 | 382 Thousand USD | 118.29% |
| 2014 | 175 Thousand USD | -39.71% |
| 2013 | 290.26 Thousand USD | 97.63% |
| 2012 | 146.87 Thousand USD | -50.4% |
| 2011 | 296.13 Thousand USD | -52.24% |
| 2010 | 620.09 Thousand USD | -83.57% |
| 2009 | 3.77 Million USD | 189.53% |
| 2008 | 1.3 Million USD | 7.88% |
| 2007 | 1.2 Million USD | 102.87% |
| 2006 | 595.45 Thousand USD | 0.81% |
| 2005 | 590.68 Thousand USD | 200.9% |
| 2004 | 196.3 Thousand USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 2266.00 USD | -75.67% |
| 2001 | 9312.00 USD | -62.57% |
| 2000 | 24.87 Thousand USD | -32.76% |
| 1999 | 36.99 Thousand USD | -38.72% |
| 1998 | 60.37 Thousand USD | -21.17% |
| 1997 | 76.59 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | - USD | 0.0% |
| 2024 Q1 | 3.55 Million USD | -77.94% |
| 2024 Q2 | - USD | -100.0% |
| 2023 Q1 | 62.54 Million USD | 98.09% |
| 2023 Q2 | 146.26 Million USD | 133.86% |
| 2023 Q4 | 16.09 Million USD | 1.72% |
| 2023 FY | 240.73 Million USD | -1.03% |
| 2023 Q3 | 15.82 Million USD | -89.18% |
| 2022 Q4 | 31.57 Million USD | -2.58% |
| 2022 Q2 | 151.8 Million USD | 453.25% |
| 2022 Q1 | 27.43 Million USD | -28.33% |
| 2022 FY | 243.23 Million USD | 75.89% |
| 2022 Q3 | 32.41 Million USD | -78.65% |
| 2021 Q4 | 38.28 Million USD | -16.58% |
| 2021 FY | 138.28 Million USD | 57.16% |
| 2021 Q1 | 21.3 Million USD | 179.1% |
| 2021 Q2 | 32.81 Million USD | 54.02% |
| 2021 Q3 | 45.89 Million USD | 39.86% |
| 2020 Q3 | 27.37 Million USD | 16.35% |
| 2020 Q4 | 7.63 Million USD | -72.12% |
| 2020 Q2 | 23.52 Million USD | -20.12% |
| 2020 FY | 87.99 Million USD | -47.87% |
| 2020 Q1 | 29.45 Million USD | -31.96% |
| 2019 Q1 | 34.65 Million USD | 207.93% |
| 2019 Q3 | 42.69 Million USD | -11.32% |
| 2019 Q4 | 43.29 Million USD | 1.4% |
| 2019 Q2 | 48.14 Million USD | 38.92% |
| 2019 FY | 168.79 Million USD | 945.67% |
| 2018 Q3 | 727.37 Thousand USD | 11.88% |
| 2018 FY | 16.14 Million USD | -48.6% |
| 2018 Q4 | 11.25 Million USD | 1447.34% |
| 2018 Q2 | 650.12 Thousand USD | -81.48% |
| 2018 Q1 | 3.5 Million USD | -59.72% |
| 2017 Q1 | 4.36 Million USD | 13869.59% |
| 2017 FY | 31.4 Million USD | 19736.49% |
| 2017 Q2 | 8.98 Million USD | 105.84% |
| 2017 Q4 | 8.71 Million USD | -6.73% |
| 2017 Q3 | 9.34 Million USD | 3.97% |
| 2016 Q3 | 39.58 Thousand USD | -9.52% |
| 2016 Q2 | 43.75 Thousand USD | 0.0% |
| 2016 Q4 | 31.25 Thousand USD | -21.05% |
| 2016 FY | 158.33 Thousand USD | -58.55% |
| 2016 Q1 | 43.75 Thousand USD | 0.0% |
| 2015 Q4 | 43.75 Thousand USD | -64.65% |
| 2015 FY | 382 Thousand USD | 118.29% |
| 2015 Q3 | 123.75 Thousand USD | 182.86% |
| 2015 Q2 | 43.75 Thousand USD | -74.38% |
| 2015 Q1 | 170.75 Thousand USD | 290.29% |
| 2014 Q1 | 43.75 Thousand USD | 0.0% |
| 2014 Q4 | 43.75 Thousand USD | 0.0% |
| 2014 Q3 | 43.75 Thousand USD | 0.0% |
| 2014 Q2 | 43.75 Thousand USD | 0.0% |
| 2014 FY | 175 Thousand USD | -39.71% |
| 2013 Q1 | 159.01 Thousand USD | 263.47% |
| 2013 Q2 | 43.75 Thousand USD | -72.49% |
| 2013 Q3 | 43.75 Thousand USD | 0.0% |
| 2013 Q4 | 43.75 Thousand USD | 0.0% |
| 2013 FY | 290.26 Thousand USD | 97.63% |
| 2012 Q1 | 23.95 Thousand USD | -99.99% |
| 2012 FY | 146.87 Thousand USD | -50.4% |
| 2012 Q4 | 43.75 Thousand USD | -8.7% |
| 2012 Q3 | 47.91 Thousand USD | 53.33% |
| 2012 Q2 | 31.25 Thousand USD | 30.44% |
| 2011 FY | 296.13 Thousand USD | -52.24% |
| 2011 Q1 | 4.99 Million USD | 2664.32% |
| 2011 Q2 | 296.13 Thousand USD | -94.07% |
| 2011 Q3 | - USD | -100.0% |
| 2011 Q4 | 290.84 Million USD | 0.0% |
| 2010 Q3 | 133.99 Thousand USD | -14.84% |
| 2010 Q4 | 180.69 Thousand USD | 34.86% |
| 2010 FY | 620.09 Thousand USD | -83.57% |
| 2010 Q1 | 148.06 Thousand USD | -26.91% |
| 2010 Q2 | 157.34 Thousand USD | 6.27% |
| 2009 FY | 3.77 Million USD | 189.53% |
| 2009 Q4 | 202.58 Thousand USD | -92.31% |
| 2009 Q1 | 701.72 Thousand USD | 1273.49% |
| 2009 Q2 | 235.65 Thousand USD | -66.42% |
| 2009 Q3 | 2.63 Million USD | 1017.42% |
| 2008 Q4 | -59.79 Thousand USD | -125.41% |
| 2008 Q3 | 235.37 Thousand USD | -67.75% |
| 2008 Q2 | 729.76 Thousand USD | 81.15% |
| 2008 Q1 | 402.86 Thousand USD | -30.3% |
| 2008 FY | 1.3 Million USD | 7.88% |
| 2007 Q2 | - USD | -100.0% |
| 2007 Q1 | 11.09 Thousand USD | -71.72% |
| 2007 FY | 1.2 Million USD | 102.87% |
| 2007 Q4 | 578.02 Thousand USD | -7.16% |
| 2007 Q3 | 622.59 Thousand USD | 0.0% |
| 2006 FY | 595.45 Thousand USD | 0.81% |
| 2006 Q3 | 246.22 Thousand USD | 328.22% |
| 2006 Q1 | 252.5 Thousand USD | 20.08% |
| 2006 Q2 | 57.5 Thousand USD | -77.23% |
| 2006 Q4 | 39.22 Thousand USD | -84.07% |
| 2005 Q3 | 173.3 Thousand USD | 123.29% |
| 2005 Q2 | 77.61 Thousand USD | -40.06% |
| 2005 Q1 | 129.49 Thousand USD | -18.61% |
| 2005 FY | 590.68 Thousand USD | 200.9% |
| 2005 Q4 | 210.27 Thousand USD | 21.33% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | 159.1 Thousand USD | 327.7% |
| 2004 Q1 | - USD | 100.0% |
| 2004 FY | 196.3 Thousand USD | 0.0% |
| 2004 Q3 | 37.2 Thousand USD | 0.0% |
| 2003 Q3 | 207.00 USD | -76.34% |
| 2003 Q1 | 1569.00 USD | 1662.92% |
| 2003 FY | - USD | -100.0% |
| 2003 Q4 | -2651.00 USD | -1380.68% |
| 2003 Q2 | 875.00 USD | -44.23% |
| 2002 Q1 | 1352.00 USD | 87.78% |
| 2002 FY | 2266.00 USD | -75.67% |
| 2002 Q4 | 89.00 USD | -67.04% |
| 2002 Q3 | 270.00 USD | -51.35% |
| 2002 Q2 | 555.00 USD | -58.95% |
| 2001 Q4 | 720.00 USD | -78.16% |
| 2001 FY | 9312.00 USD | -62.57% |
| 2001 Q2 | 95.00 USD | -98.17% |
| 2001 Q1 | 5200.00 USD | -38.36% |
| 2001 Q3 | 3297.00 USD | 3370.53% |
| 2000 Q1 | 5015.00 USD | -49.85% |
| 2000 FY | 24.87 Thousand USD | -32.76% |
| 2000 Q4 | 8436.00 USD | 74.77% |
| 2000 Q2 | 6600.00 USD | 31.61% |
| 2000 Q3 | 4827.00 USD | -26.86% |
| 1999 Q3 | 10 Thousand USD | 0.0% |
| 1999 FY | 36.99 Thousand USD | -38.72% |
| 1999 Q2 | 10 Thousand USD | 0.0% |
| 1999 Q1 | 10 Thousand USD | 0.0% |
| 1999 Q4 | 10 Thousand USD | 0.0% |
| 1998 Q2 | 30 Thousand USD | 0.0% |
| 1998 FY | 60.37 Thousand USD | -21.17% |
| 1998 Q3 | 10 Thousand USD | -66.67% |
| 1998 Q4 | 10 Thousand USD | 0.0% |
| 1997 FY | 76.59 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 163.91 Million USD | -46.867% |
| Codexis, Inc. | 70.14 Million USD | -243.206% |
| Viridian Therapeutics, Inc. | 314 Thousand USD | -76567.197% |
| Organovo Holdings, Inc. | 109 Thousand USD | -220757.798% |